The magic of sodium-glucose cotransporter-2 inhibitors: Benefits in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus: Editorial on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”
Abstract
The magic of sodium-glucose cotransporter-2 inhibitors: Benefits in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus: Editorial on "Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis"
Fields of Study & Subjects
Diabetes Treatment and Management
Liver Disease Diagnosis and Treatment
Pancreatic function and diabetes
Publication details
- Journal / source
- Clinical and Molecular Hepatology
- Volume
- 32
- Issue
- 3
- Pages
- 1413–1416
- Publication date
- 6 January 2026
- Language
- EN